The healthcare landscape shifted dramatically this week, both at the ballot box and in the boardroom. Democrats' sweeping midterm wins brought a wave of doctors and scientists into Congress, and they now have a real opening to act on their biggest campaign promise: cheaper healthcare. The party's path forward includes everything from drug price negotiations to insurance market reforms, though the political math in a narrow majority will test how bold they can actually be. The business side of medicine is also redrawing its map. CVS Health announced it will split into two companies, dismantling the $117 billion merger empire that combined drugstores, pharmacy benefits, and insurance. It's a stunning reversal of vertical integration strategy, and it signals that the era of healthcare conglomerates may be faltering. Expect rivals like UnitedHealth and Cigna to face similar pressure from investors who now doubt the synergies of "one-stop-shop" healthcare. On the clinical front, three stories deserve your attention. First, a disturbing trend: more parents are declining the vitamin K shot for newborns, putting babies at risk of life-threatening bleeding. Pediatricians are alarmed, and the research suggests social media misinformation is driving the refusal rates. Second, a major head-to-head trial found that Repatha, a PCSK9 inhibitor, cut heart attack risk by 20% compared to Zetia in patients who can't reach LDL targets with statins alone. That's a meaningful data point for the millions on cholesterol therapy. And third, the Wegovy oral tablet has been approved in Australia, marking the first pill form of semaglutide. It won't replace injections for everyone, but it offers a cheaper, more accessible entry point to GLP-1 weight loss drugs, which could reshape how these treatments are prescribed globally. Finally, two quieter but worthwhile items: the first human bird flu death has revived pandemic preparedness concerns, and a Johns Hopkins study links unintentional daytime napping to higher dementia risk, though the causality likely runs both ways. The bigger takeaway is that healthcare is being reshaped from every angle right now, politically, economically, and clinically. Keep an eye on how the CVS breakup and Democratic drug pricing plans collide over the next year.